The company’s director of clinical trial diversity strategy, Lorena Kuri, talked to Scrip about how she became interested in trial diversity and what BMS is doing to increase it.
Like all the drug makers that have lately made a priority of improving clinical trial diversity, Bristol Myers Squibb Company knows it faces numerous obstacles, some of which could take significant investment to overcome. Meeting that challenge is all in a day’s work for BMS’ director of clinical trial diversity strategy, Lorena Kuri.
“I’m privileged enough to be in a company that has been looking at this way before the pandemic hit,” Kuri...
Congratulations to the winners of the 2024 Citeline Awards, held 8 May in Boston.
Recognize your clinical research team, excellence in patient recruitment, technology initiatives, partnerships, diversity and inclusion efforts and more. Enter now to avoid the late submission fees.
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.
Global crises and a tough funding environment mean biopharma leadership teams need to work hard to survive, let alone thrive. Industry executives shared their predictions and advice on strategy for 2024.
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.
Global crises and a tough funding environment mean biopharma leadership teams need to work hard to survive, let alone thrive. Industry executives shared their predictions and advice on strategy for 2024.
MSD India managing director Rehan Khan shares with Scrip glimpses of his life and professional journey, including diversity, equity and inclusion values imbibed in his childhood, co-founding an early-stage venture fund, widening access to Keytruda to roughly “six times more patients” in the country and initiatives around HPV vaccination.
